Electromed Q1 2027 earnings
Record Q1 FY2027 with double-digit revenue growth and a 30.7% increase in operating income, supported by a 80.0% gross margin.
Headline numbers
| Metric | Actual | YoY | QoQ | 8-K location |
|---|---|---|---|---|
| Revenue | $18.7M | +10.6% | — | Ex. 99.1, income statement |
| EPS (GAAP) | $0.32 | +28.0% | — | Ex. 99.1, income statement |
Revenue breakdown
| Segment | Actual | YoY | Share of revenue | Note |
|---|---|---|---|---|
| Direct homecare | $17.5M | +17.6% | 93.5% | Revenue per rep $1.109M within target |
| Non-homecare | $1.2M | — | 6.5% | Hospital -31.6%, Distributor -55.9% |
Margins and costs
- Gross margin 80.0% (prior 78.1%, change +1.9 pp)
- Operating expenses $11.2M (+8.6% YoY)
- One-offs in the quarter not stated in the 8-K
- Effective tax rate 24.1% (prior 23.8%, change +0.3 pp)
- Non-GAAP bridge Share-based compensation expense of $435,000 added back to GAAP net income to calculate adjusted results.
KPIs
| Metric | Actual | Prior quarter | Prior year | Change |
|---|---|---|---|---|
| Cash | $15.9M | $20.5M | $15.3M | -$4.6M |
| Homecare revenue per rep | $1,109,000 | $1,145,000 | $1,145,000 | -$36,000 |
| Repurchases | $4.3M | $3.9M | $10.0M | -$0.4M |
Guidance
not stated in the 8-K
What drove it
- Revenue story Direct homecare revenue grew 17.6% to $17.5M; non-homecare revenue declined 6.7% to $1.2M.
- EPS story EPS increased 28.0% to $0.32, driven by higher net income and a slight decrease in diluted shares outstanding.
- One-off check None disclosed.
The good
- Record Q1 FY2027 with 16th consecutive quarter of YoY growth.
- Gross margin expanded to 80.0%.
- Operating income increased 30.7%.
- Homecare revenue per rep ($1.109M) within target range.
The bad
- Non-homecare revenue declined 31.6% YoY.
- SG&A expenses increased 8.6%.
- Cash balance decreased $4.6M due to share repurchases.
The ugly
- none
Open questions
- What is the outlook for non-homecare revenue?
- What is the expected pace of share repurchases?
Full release
Electromed (ELMD) earnings release, November 10, 2026
Electromed, Inc. Delivers Continued Growth in Fiscal 2027
First
Quarter
16th consecutive quarter of year-over-year revenue and operating income growth
NEW PRAGUE, Minn.--(BUSINESS WIRE)-- Electromed, Inc. (“Electromed”) (NYSE American: ELMD), a leader in innovative airway clearance technologies, today announced financial results for the three months ended September 30, 2026
(“
Q1
FY
2027”).
Q1
FY
2027
Company Highlights
“We delivered our 16th consecutive quarter of year-over-year revenue and operating income growth, with double-digit revenue growth, a 30.7% increase in operating income and an 80.0% gross margin—demonstrating the strength of our direct-to-patient model and operating leverage. We also returned $4.3 million to shareholders through share repurchases while remaining debt-free. With a strong balance sheet and high-performing sales and fulfillment teams, Electromed is well positioned to bring SmartVest® therapy to more patients who need to breathe easier,” said Jim Cunniff, President and Chief Executive Officer.
Q1
FY
2027
Results
All amounts below are for the three months ended
September 30, 2026, and compare to the three months ended
September 30, 2025
(“
Q1
FY
2026”).
Net revenues grew
10.6% to $
18.7 million, from $
16.9 million.
Revenue in our direct homecare business increased by
17.6% to $
17.5 million, from $
14.9 million. The increase in revenue was primarily due to an increase in sales representatives and increased sales representative productivity. Throughout
Q1 FY 2027, we averaged⁶³ homecare field sales representatives. The annualized homecare revenue per weighted average direct sales representative in
Q1
FY
2027 was $1,109,000, within Electromed’s target range for the year of $1,050,000 to $1,150,000.
Non-homecare revenue was $
1.2 million. Hospital revenue was $
0.7 million, a decrease of
31.6%. Homecare distributor revenue was $
0.4 million, a decrease of
55.9%. Other revenue was $
0.1 million, a decrease of
23.0%.
Gross profit increased year-over-year to $
14.9 million or
80.0% of net revenues from $
13.2 million or
78.1% of net revenues. The increase in gross profit was primarily a result of increased overall revenue and the increase in gross profit percentage was due to revenue mix.
Selling, general and administrative (“SG&A”) expenses were $
11.2 million, representing an increase of $
0.9 million, or
8.6%. The increase in the current period was primarily due to increased salaries and incentive compensation, travel and meals related to the higher average sales representative headcount and higher overall compensation costs.
Operating income was $
3.5 million or
18.7% of net revenues, compared to $
2.7 million, or
15.8% of net revenues. The
30.7% increase in operating income was primarily due to the increases in revenue and gross profit.
Net income increased by
29.3% to $
2.8 million, or $
0.32 per diluted share, compared to $
2.1 million, or $
0.25 per diluted share.
As of
September 30, 2026, Electromed had $
15.9 million in cash, $
30.3 million in accounts receivable and no debt, achieving a working capital of $
44.9 million and total shareholders’ equity of $
52.5 million. The cash balance reflects a decrease of $
4.6 million for the three months ended September 30, 2026, compared to a decrease in cash of $
1.2 million in the three months ended September 30, 2025. The decrease in cash for the three months ended September 30, 2026, was driven primarily by share repurchases of $
4.3 million of Electromed common stock.
Conference Call and Webcast Information
The conference call with members of Electromed management will be held at 5:00 p.m. Eastern Time on Tuesday, November 10, 2026.
Interested parties may participate in the call by dialing (877) 407-3982 (Domestic) or (201) 493-6780 (International).
The live conference call webcast will be accessible in the Investor Relations section of Electromed’s website and directly via the following link: https://viavid.webcasts.com/starthere.jsp?ei=1778024&tp_key=72949ff6b5
For those who cannot listen to the live broadcast, a replay will be available by dialing (844) 512-2921 (Domestic) or (412) 317-6671 (International) and referencing the Access ID 13763053. Additionally, an online replay of the webcast will be available for one year in the Investor Relations section of Electromed’s web site at: https://investors.smartvest.com/events-and-presentations/default.aspx
About Electromed, Inc.
Electromed, Inc. manufactures, markets, and sells products that provide airway clearance therapy, including the SmartVest® Airway Clearance System, to patients with compromised pulmonary function. It is headquartered in New Prague, Minnesota, and was founded in 1992. Further information about Electromed can be found at www.smartvest.com.
Financial statements
Income Statement
Three Months Ended — Condensed Statements of Operations (Unaudited)
| Three Months Ended – September 30, – 2026 | Three Months Ended – September 30, – 2025 | |
|---|---|---|
| Net revenues | 18,682,000 | 16,887,000 |
| Cost of revenues | 3,745,000 | 3,690,000 |
| Gross profit | 14,937,000 | 13,197,000 |
| Operating expenses | ||
| Selling, general and administrative | 11,171,000 | 10,286,000 |
| Research and development | 277,000 | 241,000 |
| Total operating expenses | 11,448,000 | 10,527,000 |
| Operating income | 3,489,000 | 2,670,000 |
| Interest income, net | 148,000 | 134,000 |
| Income before income taxes | 3,637,000 | 2,804,000 |
| Income tax expense | 876,000 | 668,000 |
| Net income | 2,761,000 | 2,136,000 |
| Earnings per share: | ||
| Basic | 0.33 | 0.26 |
| Diluted | 0.32 | 0.25 |
| Weighted-average common shares outstanding: | ||
| Basic | 8,307,125 | 8,322,782 |
| Diluted | 8,761,404 | 8,681,703 |
Balance Sheet
September 30, 2026 — Condensed Balance Sheets
| September 30, 2026 – (Unaudited) | June 30, 2026 | |
|---|---|---|
| Current Assets | ||
| Cash and cash equivalents | 15,875,000 | 20,450,000 |
| Accounts receivable (net of allowance for credit losses of $75,000 and $45,000 as of September 30, 2026, and June 30, 2026, respectively) | 30,267,000 | 29,805,000 |
| Contract assets | 1,026,000 | 1,094,000 |
| Inventories | 3,811,000 | 3,681,000 |
| Income tax receivable | 405,000 | 1,168,000 |
| Prepaid expenses and other current assets | 810,000 | 1,170,000 |
| Total current assets | 52,194,000 | 57,368,000 |
| Property and equipment, net | 5,168,000 | 5,214,000 |
| Finite-life intangible assets, net | 379,000 | 379,000 |
| Other assets | 1,317,000 | 1,270,000 |
| Deferred income taxes | 2,036,000 | 2,036,000 |
| Total assets | 61,094,000 | 66,267,000 |
| Current Liabilities | ||
| Accounts payable | 2,347,000 | 2,643,000 |
| Accrued compensation | 2,830,000 | 6,071,000 |
| Warranty reserve, current portion | 534,000 | 1,899,000 |
| Other accrued liabilities | 1,550,000 | 1,609,000 |
| Total current liabilities | 7,261,000 | 12,222,000 |
| Long-term warranty reserve | 1,310,000 | |
| Other long-term liabilities | 50,000 | 66,000 |
| Total liabilities | 8,621,000 | 12,288,000 |
| Shareholders’ Equity | ||
| Common stock, $0.01 par value per share, 13,000,000 shares authorized; 8,236,585 and 8,366,163 shares issued and outstanding, as of September 30, 2026, and June 30, 2026, respectively | 82,000 | 84,000 |
| Additional paid-in capital | 25,421,000 | 25,331,000 |
| Retained earnings | 26,970,000 | 28,564,000 |
| Total shareholders’ equity | 52,473,000 | 53,979,000 |
| Total liabilities and shareholders’ equity | 61,094,000 | 66,267,000 |
Cash Flow
Three Months Ended September 30, — Condensed Statements of Cash Flows (Unaudited)
| Three Months Ended September 30, – 2026 | Three Months Ended September 30, – 2025 | |
|---|---|---|
| Cash Flows From Operating Activities | ||
| Net income | 2,761,000 | 2,136,000 |
| Adjustments to reconcile net income to net cash provided by operating activities: | ||
| Depreciation | 217,000 | 214,000 |
| Amortization | 49,000 | 45,000 |
| Share-based compensation expense | 435,000 | 458,000 |
| Changes in operating assets and liabilities: | ||
| Accounts receivable | -462,000 | -96,000 |
| Contract assets | 68,000 | -134,000 |
| Inventories | -154,000 | -515,000 |
| Prepaid expenses and other assets | 284,000 | -241,000 |
| Income tax receivable, net | 763,000 | 202,000 |
| Accounts payable and accrued liabilities | -347,000 | 448,000 |
| Accrued compensation | -3,241,000 | -2,348,000 |
| Net cash provided by operating activities | 373,000 | 169,000 |
| Cash Flows From Investing Activities | ||
| Expenditures for property and equipment | -165,000 | -252,000 |
| Expenditures for finite-life intangible assets | -37,000 | -15,000 |
| Net cash used for investing activities | -202,000 | -267,000 |
| Cash Flows From Financing Activities | ||
| Issuance of common stock upon exercise of options | 48,000 | 156,000 |
| Taxes paid on net share settlement of stock awards | -466,000 | -229,000 |
| Repurchase of common stock | -4,328,000 | -1,003,000 |
| Net cash used for financing activities | -4,746,000 | -1,076,000 |
| Net decrease in cash and cash equivalents | -4,575,000 | -1,174,000 |
| Cash and cash equivalents | ||
| Beginning of period | 20,450,000 | 15,287,000 |
| End of period | 15,875,000 | 14,113,000 |
Cautionary Statements... (truncated)ssociated with such statements. Examples of risks and uncertainties for Electromed include, but are not limited to, our ability to obtain and maintain reimbursement from Medicare, Medicaid, or private insurance payers for our products; component or raw material shortages, changes to lead times or significant price increases, inflationary trends in electronic components, and uncertainty related to trade regulations (including, but not limited to, changes to tariffs); adverse changes to state and federal health care regulations; our ability to maintain regulatory compliance and to gain future regulatory approvals and clearances; entry of new competitors including new drug or pharmaceutical discoveries; adverse economic and business conditions or intense competition; our ability to attract, train and retain personnel and remain competitive with wage inflation; rising energy costs and geopolitical conflicts; technical problems with our research and products; the risks associated with cyberattacks, data breaches, computer viruses and other similar security threats; changes affecting the medical device industry; our ability to develop new sales channels for our products such as the hospital or homecare distributor channels; adverse international health care regulation impacting current international business; our ability to renew our line of credit or obtain additional credit as necessary; and our ability to protect and expand our intellectual property portfolio, as well as other factors we may describe from time to time in Electromed’s reports filed with the Securities and Exchange Commission (including Electromed’s most recent Annual Report on Form 10-K, as amended from time to time, and subsequent Quarterly Reports on Form 10-Q and Current Reports on Form 8-K). Investors should not consider any list of such factors to be an exhaustive statement of all the risks, uncertainties or potentially inaccurate assumptions investors should take into account when making investment decisions. Shareholders and other readers should not place undue reliance on “forward-looking statements,” as such statements speak only as of the date of this press release. We undertake no obligation to update them in light of new information or future events.
Brad Nagel, Chief Financial Officer
(952) 758-9299 investorrelations@electromed.com
Mike Cavanaugh, Investor Relations
ICR Healthcare
(617) 877-9641 mike.cavanaugh@icrhealthcare.com
Source: Electromed, Inc.
Electromed, Inc.
Condensed Balance Sheets
Electromed, Inc.
Condensed Statements of Operations (Unaudited)
Electromed, Inc.
Condensed Statements of Cash Flows (Unaudited)